Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
11 04 2023
Historique:
accepted: 21 07 2022
received: 07 03 2022
medline: 4 4 2023
pubmed: 12 10 2022
entrez: 11 10 2022
Statut: ppublish

Résumé

Inadequate mobilization of peripheral blood progenitor cells (PBPCs) is a limiting factor to proceeding with autologous hematopoietic cell transplantation (auto-HCT). To assess the impact of clonal hematopoiesis (CH) on mobilization failure of PBPC for auto-HCT, we investigated the characteristics of poor mobilizers (with a total PBPC collection <2 × 106 CD34+ cells per kg) in a consecutive single-center cohort of 776 patients. Targeted error-corrected next-generation sequencing of 28 genes was performed in a nested case-control cohort of 90 poor mobilizers and 89 matched controls. CH was detected in 48 out of 179 patients (27%), with most patients carrying a single mutation. The presence of CH (detected at variant allele frequency [VAF] ≥ 1%) did not associate with poor mobilization potential (31% vs 22% in controls, odds ratio, 1.55; 95% confidence interval, 0.76-3.23; P = .238). PPM1D mutations were detected more often in poor mobilizers (P = .005). In addition, TP53 mutations in this cohort were detected exclusively in patients with poor mobilization potential (P = .06). The incidence of therapy-related myeloid neoplasms (t-MN) was higher among patients with mobilization failure (P = .014). Although poor mobilizers experienced worse overall survival (P = .019), this was not affected by the presence of CH. We conclude that CH at low VAF (1%-10%) is common at the time of stem cell mobilization. TP53 mutations and PPM1D mutations are associated with poor mobilization potential and their role in subsequent development of t-MN in these individuals should be established.

Identifiants

pubmed: 36219593
pii: 486755
doi: 10.1182/bloodadvances.2022007497
pmc: PMC10119633
doi:

Substances chimiques

Antigens, CD34 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1269-1278

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Leukemia. 2021 Jul;35(7):2125-2129
pubmed: 33184493
N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
J Clin Oncol. 2019 Feb 10;37(5):375-385
pubmed: 30403573
Bone Marrow Transplant. 2012 Mar;47(3):342-51
pubmed: 21625224
EMBO J. 2000 Dec 1;19(23):6517-26
pubmed: 11101524
Blood. 2018 Apr 19;131(16):1846-1857
pubmed: 29311096
Cell Stem Cell. 2018 Nov 1;23(5):700-713.e6
pubmed: 30388424
Blood. 2022 Oct 20;140(16):1753-1763
pubmed: 35512188
Blood. 2021 Nov 25;138(21):2093-2105
pubmed: 34125889
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
J Clin Oncol. 1995 Oct;13(10):2547-55
pubmed: 7595706
Blood. 2008 Jan 1;111(1):94-100
pubmed: 17895401
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4
pubmed: 28803919
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Cancer. 2020 Feb 15;126(4):765-774
pubmed: 31742675
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
Blood. 2017 Aug 10;130(6):742-752
pubmed: 28483762
Nat Genet. 2020 Nov;52(11):1219-1226
pubmed: 33106634
Br J Haematol. 2021 May;193(4):841-844
pubmed: 33481245
Nat Commun. 2018 Jan 31;9(1):455
pubmed: 29386642
Am J Hematol. 2009 Jun;84(6):335-7
pubmed: 19384931
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6048-53
pubmed: 9177166
Nature. 2015 Feb 26;518(7540):552-555
pubmed: 25487151
Blood. 2009 Jun 4;113(23):5720-6
pubmed: 19363221
Haematologica. 2020 Jul;105(7):e337-e339
pubmed: 31699793
Blood Adv. 2020 Mar 10;4(5):885-892
pubmed: 32150606
Blood. 2020 Apr 2;135(14):1161-1170
pubmed: 32243522
Blood Adv. 2020 Nov 24;4(22):5681-5689
pubmed: 33211826
Blood. 2018 Sep 13;132(11):1095-1105
pubmed: 29954749
Transfus Apher Sci. 2009 Aug;41(1):33-7
pubmed: 19540167
Nat Commun. 2020 Jun 12;11(1):2996
pubmed: 32533060
Leukemia. 2020 Dec;34(12):3256-3268
pubmed: 32203146
Lancet Oncol. 2017 Jan;18(1):100-111
pubmed: 27923552
Br J Haematol. 2003 Feb;120(3):413-23
pubmed: 12580955
Br J Haematol. 2019 Aug;186(3):e31-e35
pubmed: 30859554
J Clin Oncol. 2017 May 10;35(14):1598-1605
pubmed: 28068180
Haematologica. 2013 Mar;98(3):364-70
pubmed: 23242601
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
Biol Blood Marrow Transplant. 2010 Apr;16(4):490-9
pubmed: 19925876
Lancet Oncol. 2017 Jan;18(1):112-121
pubmed: 27927582
Blood Adv. 2021 Apr 27;5(8):2115-2122
pubmed: 33877299

Auteurs

Carin L E Hazenberg (CLE)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Aniek O de Graaf (AO)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

René Mulder (R)

Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Laura B Bungener (LB)

Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Maaike G J M van Bergen (MGJM)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

André B Mulder (AB)

Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Goda Choi (G)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Jan Jacob Schuringa (JJ)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Marco R de Groot (MR)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Edo Vellenga (E)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Joop H Jansen (JH)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

Gerwin Huls (G)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Isabelle A van Zeventer (IA)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH